DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Global
Uterine Fibroids Market: Industry Analysis & Outlook (2017-2025)”
report to their offering.
Global Uterine Fibroids Drugs Market: Industry Analysis & Outlook
(2017-2025) analyzes the development of this market, with focus on the
US and European markets. The major trends, growth drivers, as well as
issues being faced by the market are discussed in detail in this report.
The global uterine market has no direct indication-approved drug.
Gonadotropin-releasing hormone analogues (GnRHa) agents are used to
reduce size of tumors and reduce blood loss to correct anemia. With the
launch of two potential drug candidates, Relugolix and Elagolix, the
market will experience robust growth with higher penetration rate to
treat women with this disease. The US will promulgate the introduction
of these drugs and will be the largest market for uterine fibroids.
The global uterine fibroids drugs market is expected to experience
robust growth post the launch of therapeutic drugs, primarily due to
increasing patient base, rise in female population, and increasing
healthcare expenditure. However, the market growth is hindered by high
R&D costs and regulatory warnings.
The major trends of the market includes development of new drugs,
increase in demand for minimal invasive surgeries, and expansion of new
technologies. However, the market will be hindered by tough regulatory
warnings and high R&D costs.
The four major players: AbbVie, Myovant Sciences, Astra Zeneca, and
Neurocrine Biosciences are being profiled along with their key
financials and strategies for growth. The report contains a
comprehensive analysis of the global uterine fibroids market along with
the study of the regional markets.
- Increasing Female Population Worldwide
- Rising Spending on Public Health Programs for Females
- Growing Uterine Fibroids Market in Emerging Economies
- Increased Spending on Medicines
Increasing Global Healthcare Expenditure
Trends and Developments
- Development of New Drugs
- Increasing Demand for Minimally Invasive Surgeries
- Expansion of More Efficient and Advanced Technology
Issues and Challenges
- FDA’s Black Box Warnings
- High R&D Costs
- Drug Progress Challenges in Developing Countries
- Myovant Sciences Ltd. (Roivant Sciences, Ltd.)
- Neurocrine Biosciences
For more information about this report visit http://www.researchandmarkets.com/research/7rdrqr/global_uterine
Research and Markets
Laura Wood, Senior Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Fax (outside U.S.): +353-1-481-1716